Overview

Trial of Consolidation Pembrolizumab After Concurrent Chemotherapy and Proton Reirradiation for Thoracic Recurrences of Non-Small Cell Lung Cancer

Status:
Recruiting

Trial end date:
2021-12-18

Target enrollment:

Participant gender:

Summary

The main purpose of this study is to assess the safety, tolerability and anti-tumor activity of the experimental study drug pembrolizumab (also known as Keytruda or MK-3475) in people with non-small cell lung cancer (NSCLC) that has come back after radiation therapy.

Phase:

Phase 2

Details

Lead Sponsor:

Abramson Cancer Center of the University of Pennsylvania

Treatments:

Pembrolizumab